Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Regenerative MedicineCell Therapy

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1944725

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1944725

Cell Therapy Technologies Market by Product, Process, Type, Application - Global Forecast to 2030

PUBLISHED:
PAGES: 432 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global cell therapy technologies market is projected to reach USD 7.91 billion in 2030 from USD 4.41 billion in 2025, with a significant CAGR of 12.4% from 2025 to 2030.

Scope of the Report
Years Considered for the Study2023-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsProduct, Process, Cell Type, Application, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East, and Africa

The market is experiencing strong growth, driven by advancements in regenerative medicine, the rising prevalence of chronic diseases, increasing investments in research and development, and innovations in gene editing tools, such as CRISPR. Regulatory support and government funding, along with strategic collaborations between biotech firms and academic institutions, are propelling the development of novel cell therapies, thereby driving market growth.

Cell Therapy Technologies Market - IMG1

"The T-cells segment is projected to record the highest CAGR during the forecast period."

The cell therapy technologies market is categorized into three primary categories based on cell type: T cells, stem cells, and other cell types. The T-cell segment is expected to grow at the fastest rate during the forecast period, driven by the strong clinical and commercial momentum of CAR-T and TCR therapies in cancer and their expansion into solid tumor indications. Furthermore, increasing regulatory approvals, favorable reimbursement decisions in significant markets, and growing physician familiarity with T-cell immunotherapies are encouraging broader adoption, which in turn boosts demand for specialized media, gene-editing tools, bioreactors, and analytics tailored to T-cell workflows within the cell therapy technology market.

"The cancer application segment accounted for the largest share in 2024."

The application segment in the cell therapy technologies market includes cancer, cardiovascular disease (CVD), orthopaedic disorders, autoimmune diseases, and other applications. The cancer application segment dominated in 2024 due to the increasing prevalence of cancer globally and the rising demand for innovative, targeted therapies. Advancements in cell engineering, scalable manufacturing, and emerging applications in solid tumors further enhance the growth potential of this segment. It possesses a solid clinical pipeline, and government initiatives are highly supportive, with regulatory approvals facilitating the segment's growth.

"The US dominated the North American cell therapy technologies market in 2024."

The US is the largest biopharmaceutical market globally and a key hub for cell and gene therapy innovation, making it a core demand center for cell therapy technologies, products, and services. Demand is expected to rise further, supported by a sophisticated research ecosystem, strong venture and public funding, and the presence of foremost CGT technology leaders, including Thermo Fisher Scientific, Danaher, and Merck. The country benefits from substantial NIH and BARDA support for advanced therapies, as well as large precision medicine and population-scale CGT initiatives run through leading academic and cancer centers. The high uptake of automated cell processing platforms, digital manufacturing, and advanced analytics across clinical and commercial facilities reinforces the US market's leadership. In addition, a mature regulatory framework, robust healthcare infrastructure, and active public-private collaborations continue to foster rapid translation and commercialization of new cell therapy technologies in the US.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side (70%) and Demand Side (30%)
  • By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
  • By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc. (US), Avantor, Inc. (US), Bio-Techne (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US), Terumo Corporation (Japan), GenScript (US), MaxCyte (US) and STEMCELL Technologies (Canada) are some of the major players operating in the cell therapy technologies market.

Research Coverage:

This research report categorizes the cell therapy technologies market by product (media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products), process (cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control), cell type (T-cells, stem cells, and other cells), application (cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications) end user (biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The report's scope encompasses detailed information regarding the key factors, including drivers, restraints, challenges, and opportunities, that influence market growth. A thorough analysis of key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, and acquisitions are recent developments in the cell therapy technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (expanding base of approved CGTs and a growing clinical pipeline, growing capital investments in CGT manufacturing capacity, scale-up of allogeneic and iPSC-derived platforms) restraints (high therapy cost and uncertain reimbursement limiting commercial volumes), opportunities (platformized, modular manufacturing solutions for autologous therapies, integration with digital technologies such as AI & ML), and challenges (lack of skilled workforce in CGT manufacturing and automation) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.
  • Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell therapy technologies market.
  • Competitive Assessment: Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), among others in the market.
Show more
Product Code: BT 6823

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW
  • 3.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY, 2024
  • 3.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2025 VS. 2030
  • 3.4 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Expanding base of approved CGTs and growing clinical pipeline
      • 4.2.1.2 Large capital investments in CGT manufacturing capacity
      • 4.2.1.3 Growing shift towards closed and automated manufacturing
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Manufacturing and logistical complexity
      • 4.2.2.2 High therapy cost and uncertain reimbursement limit commercial volumes
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Platformized and modular manufacturing solutions for autologous therapies
      • 4.2.3.2 Development of personalized and off-the-shelf cell therapies
      • 4.2.3.3 Integration with digital technologies
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Lack of skilled workforce in CGT manufacturing and automation
  • 4.3 UNMET NEEDS & WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 COMPANIES

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 BARGAINING POWER OF SUPPLIERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
    • 5.2.3 TRENDS IN CELL THERAPY TECHNOLOGIES MARKET
    • 5.2.4 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
    • 5.2.5 R&D TRENDS IN GLOBAL PHARMA INDUSTRY
  • 5.3 ECOSYSTEM ANALYSIS
    • 5.3.1 ROLE IN ECOSYSTEM
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022-2024
    • 5.4.2 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2022-2024
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 TRADE ANALYSIS
    • 5.6.1 IMPORT SCENARIO FOR HS CODE 854330
    • 5.6.2 IMPORT VOLUME FOR HS CODE 854330
    • 5.6.3 EXPORT SCENARIO FOR HS CODE 854330, 2020-2024
    • 5.6.4 EXPORT VOLUME FOR HS CODE 854330
  • 5.7 KEY CONFERENCES AND EVENTS, 2026
  • 5.8 INVESTMENT & FUNDING SCENARIO
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • 5.10 IMPACT OF 2025 US TARIFF ON CELL THERAPY TECHNOLOGIES MARKET
    • 5.10.1 KEY TARIFF RATES
    • 5.10.2 PRICE IMPACT ANALYSIS
    • 5.10.3 KEY IMPACT ON COUNTRIES/ REGION
      • 5.10.3.1 US
      • 5.10.3.2 Europe
      • 5.10.3.3 Asia Pacific
    • 5.10.4 END-USE INDUSTRY IMPACT
      • 5.10.4.1 Biopharmaceutical and Biotechnology Companies
      • 5.10.4.2 CROs and CMOs
      • 5.10.4.3 Cell Banks

6 TECHNOLOGICAL ADVANCEMENTS, AI IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 TECHNOLOGY ANALYSIS
    • 6.1.1 KEY EMERGING TECHNOLOGIES
      • 6.1.1.1 Magnetic-activated cell sorting
      • 6.1.1.2 Cryopreservation
      • 6.1.1.3 Bioprocessing technologies
    • 6.1.2 COMPLEMENTARY TECHNOLOGIES
      • 6.1.2.1 Artificial intelligence and machine learning
      • 6.1.2.2 Gene editing technologies
    • 6.1.3 ADJACENT TECHNOLOGIES
      • 6.1.3.1 Nanotechnology
      • 6.1.3.2 Immunotherapy platforms
  • 6.2 TECHNOLOGY/PRODUCT ROADMAP
  • 6.3 PATENT ANALYSIS
    • 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL THERAPY TECHNOLOGIES PATENTS, 2014-2024
  • 6.4 FUTURE APPLICATIONS
  • 6.5 IMPACT OF AI/GEN AI ON CELL THERAPY TECHNOLOGIES MARKET
    • 6.5.1 TOP USE CASES AND MARKET POTENTIAL
    • 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN CELL THERAPY TECHNOLOGIES MARKET
    • 6.5.3 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN CELL THERAPY TECHNOLOGIES MARKET

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

  • 7.1 REGULATORY LANDSCAPE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 INDUSTRY STANDARDS
      • 7.1.2.1 North America
      • 7.1.2.2 Europe
      • 7.1.2.3 Asia Pacific
      • 7.1.2.4 Rest of the World
    • 7.1.3 SUSTAINABILITY INITIATIVES, IMPACT, AND REGULATORY POLICY INITIATIVES
    • 7.1.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 KEY STAKEHOLDERS & BUYING CRITERIA
    • 8.2.1 KEY STAKEHOLDERS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 MEDIA, SERA, AND REAGENTS
    • 9.2.1 KEY IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET
  • 9.3 CELL THERAPY EQUIPMENT
    • 9.3.1 CELL PROCESSING EQUIPMENT
      • 9.3.1.1 Development of automated and closed-system cell processing equipment to accelerate segment growth
    • 9.3.2 SINGLE-USE EQUIPMENT
      • 9.3.2.1 Increasing funding for stem cell therapy to propel market growth
    • 9.3.3 OTHER CELL THERAPY EQUIPMENT
  • 9.4 SYSTEMS & SOFTWARE
    • 9.4.1 GROWING NEED FOR CELL THERAPIES TO AID SYSTEMS AND SOFTWARE ADOPTION
  • 9.5 CELL CULTURE VESSELS
    • 9.5.1 RISING R&D AND INVESTMENTS IN CELL-BASED THERAPIES TO AUGMENT MARKET DEMAND
  • 9.6 CELL ENGINEERING PRODUCTS
    • 9.6.1 AVAILABILITY OF WIDE RANGE OF CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH
  • 9.7 OTHER PRODUCTS

10 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS

  • 10.1 INTRODUCTION
  • 10.2 CELL PROCESSING
    • 10.2.1 CELL EXPANSION
      • 10.2.1.1 Rising demand for personalized and regenerative therapies to drive market growth
    • 10.2.2 CELL ISOLATION
      • 10.2.2.1 Rising need for scalable and efficient isolation technologies to aid market growth
    • 10.2.3 CELL CHARACTERIZATION
      • 10.2.3.1 Increasing demand for high-quality, safe, and effective cell-based therapies to propel market growth
    • 10.2.4 CELL COLLECTION
      • 10.2.4.1 Advancements in cell collection technologies to propel market growth
  • 10.3 CELL PRESERVATION
    • 10.3.1 ADVANCEMENT IN CRYOPRESERVATION TECHNOLOGIES TO BOOST MARKET GROWTH
  • 10.4 PROCESS MONITORING & QUALITY CONTROL
    • 10.4.1 INCREASING DEMAND FOR AUTOMATED QUALITY CONTROL IN CELL THERAPY PRODUCTION TO FUEL MARKET GROWTH
  • 10.5 CELL HANDLING
    • 10.5.1 INCREASING DEMAND FOR AUTOMATED, EFFICIENT, AND SCALABLE SOLUTIONS TO ACCELERATE MARKET GROWTH
  • 10.6 CELL DISTRIBUTION
    • 10.6.1 INCREASED FOCUS ON TRANSPORTATION AND STORAGE TO DRIVE MARKET

11 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE

  • 11.1 INTRODUCTION
  • 11.2 T CELLS
    • 11.2.1 GROWING RESEARCH ON CAR T-CELL THERAPY TO AID MARKET GROWTH
  • 11.3 STEM CELLS
    • 11.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO PROPEL MARKET GROWTH
  • 11.4 OTHER CELLS

12 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION

  • 12.1 INTRODUCTION
  • 12.2 CANCER
    • 12.2.1 FOCUS ON CAR T-CELL INNOVATION TO DRIVE SEGMENT EXPANSION
  • 12.3 CARDIOVASCULAR DISEASES
    • 12.3.1 INCREASING FOCUS ON INNOVATIVE CELL THERAPY APPROACHES TO DRIVE MARKET
  • 12.4 ORTHOPEDIC DISORDERS
    • 12.4.1 GROWING ADOPTION OF STEM CELL THERAPY FOR TISSUE REPAIR TO SUPPORT MARKET GROWTH
  • 12.5 AUTOIMMUNE DISEASES
    • 12.5.1 RISING INVESTMENTS IN STEM CELL RESEARCH TO FUEL MARKET GROWTH
  • 12.6 OTHER APPLICATIONS

13 CELL THERAPY TECHNOLOGIES MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 13.2.1 GROWING ADOPTION OF INORGANIC GROWTH STRATEGIES BY BIOPHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH
  • 13.3 CROS & CMOS
    • 13.3.1 GROWING FOCUS ON OUTSOURCING CLINICAL-SCALE PRECLINICAL & CLINICAL TRIALS TO DRIVE GROWTH
  • 13.4 RESEARCH INSTITUTES
    • 13.4.1 RISING FOCUS ON RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
  • 13.5 CELL BANKS
    • 13.5.1 INCREASING DEMAND FOR STANDARDIZED CELL LINES TO SPUR MARKET GROWTH

14 CELL THERAPY TECHNOLOGIES MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 US
      • 14.2.1.1 US to dominate North American cell therapy technologies market during forecast period
    • 14.2.2 CANADA
      • 14.2.2.1 Favorable funding scenario to drive adoption of cell therapy instruments
  • 14.3 EUROPE
    • 14.3.1 GERMANY
      • 14.3.1.1 Well-established pharmaceutical and R&D industry to aid Germany gain significant European market share
    • 14.3.2 UK
      • 14.3.2.1 Favorable funding and investment scenario to fuel market growth
    • 14.3.3 FRANCE
      • 14.3.3.1 Availability of government and private funding to fuel market growth
    • 14.3.4 ITALY
      • 14.3.4.1 Increased focus on public and private investment to offer growth opportunities
    • 14.3.5 SPAIN
      • 14.3.5.1 Advancement in personalized medicines to stimulate market growth
    • 14.3.6 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 CHINA
      • 14.4.1.1 Focus on innovation and R&D in genetic research to drive market
    • 14.4.2 JAPAN
      • 14.4.2.1 Strong availability of funding for advanced cell therapies to aid market growth
    • 14.4.3 INDIA
      • 14.4.3.1 Substantial government R&D investments and focus of academic institutions on scientific innovation to drive market
    • 14.4.4 SOUTH KOREA
      • 14.4.4.1 Rising number of alliances and investments in research to boost market growth
    • 14.4.5 AUSTRALIA
      • 14.4.5.1 Increasing government funding and initiatives to drive market growth
    • 14.4.6 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 BRAZIL
      • 14.5.1.1 Growing development of advanced therapies and robust pharmaceutical & biotechnology sectors to aid market growth
    • 14.5.2 MEXICO
      • 14.5.2.1 Growing pharmaceutical industry and rising government support to aid market growth
    • 14.5.3 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST
    • 14.6.1 GCC COUNTRIES
      • 14.6.1.1 Kingdom of Saudi Arabia
        • 14.6.1.1.1 Increasing government investments in healthcare to support market growth
      • 14.6.1.2 UAE
        • 14.6.1.2.1 Growing R&D expenditure and well-established class infrastructure to spur market growth
      • 14.6.1.3 Rest of GCC Countries
    • 14.6.2 REST OF MIDDLE EAST
  • 14.7 AFRICA
    • 14.7.1 INCREASING HEALTH AND RESEARCH SPENDING TO PROPEL MARKET DEMAND FOR ADVANCED CELL THERAPY TECHNOLOGIES

15 COMPETITIVE LANDSCAPE

  • 15.1 INTRODUCTION
  • 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET
  • 15.3 REVENUE ANALYSIS, 2022-2024
  • 15.4 MARKET SHARE ANALYSIS, 2024
  • 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 15.5.1 STARS
    • 15.5.2 EMERGING LEADERS
    • 15.5.3 PERVASIVE PLAYERS
    • 15.5.4 PARTICIPANTS
    • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 15.5.5.1 Company footprint
      • 15.5.5.2 Region footprint
      • 15.5.5.3 Product footprint
      • 15.5.5.4 Cell type footprint
      • 15.5.5.5 Application footprint
  • 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 15.6.1 PROGRESSIVE COMPANIES
    • 15.6.2 RESPONSIVE COMPANIES
    • 15.6.3 DYNAMIC COMPANIES
    • 15.6.4 STARTING BLOCKS
    • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 15.6.5.1 Detailed list of key startups/SMEs
      • 15.6.5.2 Competitive benchmarking of startups/SMEs
  • 15.7 COMPANY VALUATION & FINANCIAL METRICS
    • 15.7.1 FINANCIAL METRICS
    • 15.7.2 COMPANY VALUATION
  • 15.8 BRAND/PRODUCT COMPARISON
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT LAUNCHES
    • 15.9.2 DEALS
    • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 DANAHER CORPORATION
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product launches
        • 16.1.1.3.2 Deals
        • 16.1.1.3.3 Expansions
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Key strengths
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses & competitive threats
    • 16.1.2 MERCK KGAA
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Deals
        • 16.1.2.3.2 Expansions
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Key strengths
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses & competitive threats
    • 16.1.3 THERMO FISHER SCIENTIFIC INC.
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Product launches
        • 16.1.3.3.2 Deals
        • 16.1.3.3.3 Expansions
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Key strengths
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses & competitive threats
    • 16.1.4 LONZA
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Product launches
        • 16.1.4.3.2 Deals
        • 16.1.4.3.3 Expansions
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Key strengths
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses & competitive threats
    • 16.1.5 SARTORIUS AG
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Deals
        • 16.1.5.3.2 Expansions
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Key strengths
        • 16.1.5.4.2 Strategic choices
        • 16.1.5.4.3 Weaknesses & competitive threats
    • 16.1.6 AGILENT TECHNOLOGIES, INC.
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products offered
      • 16.1.6.3 Recent developments
        • 16.1.6.3.1 Product launches
        • 16.1.6.3.2 Deals
      • 16.1.6.4 MnM view
        • 16.1.6.4.1 Key strengths
        • 16.1.6.4.2 Strategic choices
        • 16.1.6.4.3 Weaknesses & competitive threats
    • 16.1.7 AVANTOR, INC.
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Product launches
        • 16.1.7.3.2 Deals
    • 16.1.8 FRESENIUS SE & CO. KGAA
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Deals
    • 16.1.9 BECTON, DICKINSON AND COMPANY (BD)
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products offered
      • 16.1.9.3 Recent developments
        • 16.1.9.3.1 Product launches
        • 16.1.9.3.2 Deals
    • 16.1.10 CORNING INCORPORATED
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products offered
    • 16.1.11 TERUMO CORPORATION
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Product launches
        • 16.1.11.3.2 Deals
        • 16.1.11.3.3 Expansions
    • 16.1.12 BIO-TECHNE
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products offered
      • 16.1.12.3 Recent developments
        • 16.1.12.3.1 Product launches
        • 16.1.12.3.2 Deals
        • 16.1.12.3.3 Other developments
    • 16.1.13 GENSCRIPT
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products offered
      • 16.1.13.3 Recent developments
        • 16.1.13.3.1 Deals
        • 16.1.13.3.2 Other developments
    • 16.1.14 MAXCYTE
      • 16.1.14.1 Business overview
      • 16.1.14.2 Products offered
      • 16.1.14.3 Recent developments
        • 16.1.14.3.1 Deals
    • 16.1.15 STEMCELL TECHNOLOGIES
      • 16.1.15.1 Business overview
      • 16.1.15.2 Products offered
      • 16.1.15.3 Recent developments
        • 16.1.15.3.1 Product launches
        • 16.1.15.3.2 Deals
  • 16.2 OTHER PLAYERS
    • 16.2.1 ROOSTERBIO, INC.
    • 16.2.2 MILTENYI BIOTEC
    • 16.2.3 TRAKCEL
    • 16.2.4 L7 INFORMATICS, INC.
    • 16.2.5 REPLIGEN CORPORATION
    • 16.2.6 MAK SYSTEM
    • 16.2.7 ORIGEN BIOMEDICAL, INC.
    • 16.2.8 IXCELLS BIOTECHNOLOGIES
    • 16.2.9 KORBER AG
    • 16.2.10 KRISHGEN BIOSYSTEMS

17 RESEARCH METHODOLOGY

  • 17.1 RESEARCH DATA
    • 17.1.1 SECONDARY DATA
      • 17.1.1.1 Key objectives of secondary research
    • 17.1.2 PRIMARY DATA
      • 17.1.2.1 Breakdown of primaries
      • 17.1.2.2 Objectives of primary research
  • 17.2 MARKET ESTIMATION METHODOLOGY
    • 17.2.1 MARKET ESTIMATION
    • 17.2.2 INSIGHTS FROM PRIMARY EXPERTS
    • 17.2.3 TOP-DOWN APPROACH
  • 17.3 MARKET GROWTH RATE PROJECTIONS
  • 17.4 DATA TRIANGULATION
  • 17.5 STUDY ASSUMPTIONS
  • 17.6 RESEARCH LIMITATIONS
  • 17.7 RISK ANALYSIS

18 APPENDIX

  • 18.1 DISCUSSION GUIDE
  • 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 18.3 CUSTOMIZATION OPTIONS
  • 18.4 RELATED REPORTS
  • 18.5 AUTHOR DETAILS
Show more
Product Code: BT 6823

List of Tables

  • TABLE 1 CELL THERAPY TECHNOLOGIES MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 IMPACT OF PORTER'S FIVE FORCES ON CELL THERAPY TECHNOLOGIES MARKET
  • TABLE 3 ROLE OF COMPANIES IN ECOSYSTEM IN CELL THERAPY TECHNOLOGIES MARKET
  • TABLE 4 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
  • TABLE 5 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY REGION, 2022-2024 (USD)
  • TABLE 6 IMPORT VALUE FOR HS CODE 854330, 2020-2024 (USD THOUSAND)
  • TABLE 7 IMPORT VOLUME FOR HS CODE 854330, 2020-2024 (UNITS)
  • TABLE 8 EXPORT VALUE FOR HS CODE 854330, 2020-2024 (USD THOUSAND)
  • TABLE 9 EXPORT VOLUME FOR HS CODE 854330, 2020-2024 (UNITS)
  • TABLE 10 KEY CONFERENCES & EVENTS IN CELL THERAPY TECHNOLOGIES MARKET, JANUARY 2026-DECEMBER 2026
  • TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 12 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO CELL THERAPY TECHNOLOGIES MARKET
  • TABLE 13 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS, 2025
  • TABLE 14 CASE STUDIES OF AI IMPLEMENTATION IN CELL THERAPY TECHNOLOGIES MARKET
  • TABLE 15 CLIENT'S READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN CELL THERAPY TECHNOLOGIES MARKET
  • TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 VENDOR CERTIFICATIONS IN CELL THERAPY TECHNOLOGIES MARKET
  • TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS
  • TABLE 22 KEY BUYING CRITERIA FOR CELL THERAPY TECHNOLOGIES PRODUCTS, BY END USER
  • TABLE 23 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 24 CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 25 NORTH AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 26 EUROPE: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 27 ASIA PACIFIC: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 28 LATIN AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 29 MIDDLE EAST: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 30 GCC COUNTRIES: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 31 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 32 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 33 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 34 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 36 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 38 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 39 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 40 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 LATIN AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 MIDDLE EAST: CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 45 GCC COUNTRIES: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 47 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 LATIN AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 51 MIDDLE EAST: SINGLE-USE EQUIPMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 52 GCC COUNTRIES: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 54 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 LATIN AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 58 MIDDLE EAST: OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 59 GCC COUNTRIES: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 MAJOR CELL THERAPY SYSTEMS & SOFTWARE, BY COMPANY
  • TABLE 61 CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 62 NORTH AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 63 EUROPE: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 65 LATIN AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 MIDDLE EAST: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 67 GCC COUNTRIES: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 CELL CULTURE VESSELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 69 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 70 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 74 GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 CELL ENGINEERING PRODUCTS OFFERED BY KEY COMPANIES
  • TABLE 76 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 77 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 78 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 LATIN AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 81 MIDDLE EAST: CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 82 GCC COUNTRIES: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 84 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 LATIN AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 88 MIDDLE EAST: OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 89 GCC COUNTRIES: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 92 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 93 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 94 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 96 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 98 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 CELL EXPANSION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 100 NORTH AMERICA: CELL EXPANSION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 101 EUROPE: CELL EXPANSION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: CELL EXPANSION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 LATIN AMERICA: CELL EXPANSION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 MIDDLE EAST: CELL EXPANSION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 105 GCC COUNTRIES: CELL EXPANSION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 106 CELL ISOLATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 107 NORTH AMERICA: CELL ISOLATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 108 EUROPE: CELL ISOLATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: CELL ISOLATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 110 LATIN AMERICA: CELL ISOLATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 111 MIDDLE EAST: CELL ISOLATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 112 GCC COUNTRIES: CELL ISOLATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 113 CELL CHARACTERIZATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 114 NORTH AMERICA: CELL CHARACTERIZATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 115 EUROPE: CELL CHARACTERIZATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: CELL CHARACTERIZATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 117 LATIN AMERICA: CELL CHARACTERIZATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 118 MIDDLE EAST: CELL CHARACTERIZATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 119 GCC COUNTRIES: CELL CHARACTERIZATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 120 CELL COLLECTION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 121 NORTH AMERICA: CELL COLLECTION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 122 EUROPE: CELL COLLECTION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: CELL COLLECTION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 124 LATIN AMERICA: CELL COLLECTION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 125 MIDDLE EAST: CELL COLLECTION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 126 GCC COUNTRIES: CELL COLLECTION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 127 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 128 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 129 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 131 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 132 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 133 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 134 PROCESS MONITORING & QUALITY CONTROL MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 135 NORTH AMERICA: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 136 EUROPE: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 137 ASIA PACIFIC: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 LATIN AMERICA: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 139 MIDDLE EAST: PROCESS MONITORING & QUALITY CONTROL MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 140 GCC COUNTRIES: PROCESS MONITORING & QUALITY CONTROL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 141 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 142 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 143 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 145 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 146 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 147 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 148 CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 149 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 150 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 152 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 153 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 154 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 155 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 156 T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 157 NORTH AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 158 EUROPE: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 160 LATIN AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 161 MIDDLE EAST: T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 162 GCC COUNTRIES: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 163 STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 164 NORTH AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 165 EUROPE: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 166 ASIA PACIFIC: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 167 LATIN AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 168 MIDDLE EAST: STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 169 GCC COUNTRIES: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 170 OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 171 NORTH AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 172 EUROPE: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 173 ASIA PACIFIC: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 174 LATIN AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 175 MIDDLE EAST: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 176 GCC COUNTRIES: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 177 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 178 CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 179 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 180 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 183 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 184 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 185 CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 186 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 187 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 189 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 190 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 191 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 192 CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 193 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 194 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 195 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 196 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 197 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 198 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 199 CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 200 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 201 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 203 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 204 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 205 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 206 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 207 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 208 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 210 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 211 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 212 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 213 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 214 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 215 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 216 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 218 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 219 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 220 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 221 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 222 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 223 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 224 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 225 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 226 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 227 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 228 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 229 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 230 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 232 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 233 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 234 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 235 CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 236 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 237 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 238 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 239 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 240 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 241 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 242 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 243 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 244 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 245 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 246 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 247 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 248 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 249 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 250 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 251 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 252 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 253 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 254 US: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 255 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 256 US: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 257 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 258 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 259 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 260 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 261 CANADA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 262 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 263 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 264 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 265 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 266 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 267 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 268 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 269 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 270 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 271 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 272 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 273 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 274 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 275 GERMANY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 276 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 277 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 278 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 279 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 280 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 281 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 282 UK: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 283 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 284 UK: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 285 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 286 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 287 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 288 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 289 FRANCE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 290 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 291 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 292 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 293 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 294 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 295 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 296 ITALY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 297 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 298 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 299 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 300 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 301 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 302 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 303 SPAIN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 304 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 305 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 306 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 307 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 308 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 309 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 310 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 311 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 312 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 313 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 314 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 315 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 316 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 318 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 319 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 320 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 321 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 322 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 323 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 324 CHINA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 325 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 326 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 327 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 328 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 329 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 330 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 331 JAPAN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 332 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 333 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 334 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 335 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 336 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 337 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 338 INDIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 339 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 340 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 341 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 342 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 343 SOUTH KOREA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 344 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 345 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 346 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 347 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 348 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 349 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 350 AUSTRALIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 351 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 352 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 353 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 354 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 355 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 356 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 357 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 358 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 359 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 360 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 361 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 362 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 363 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 364 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 365 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 366 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 367 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 368 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 369 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 370 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 371 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 372 BRAZIL: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 373 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 374 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 375 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 376 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 377 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 378 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 379 MEXICO: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 380 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 381 MEXICO: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 382 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 383 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 384 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 385 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 386 REST OF LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 387 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 388 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 389 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 390 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 391 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 392 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 393 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 394 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 395 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 396 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 397 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 398 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 399 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 400 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 401 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 402 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 403 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 404 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 405 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 406 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 407 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 408 KINGDOM OF SAUDI ARABIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 409 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 410 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 411 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 412 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 413 KINGDOM OF SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 414 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 415 UAE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 416 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 417 UAE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 418 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 419 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 420 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 421 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 422 REST OF GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 423 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 424 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 425 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 426 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 427 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 428 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 429 REST OF MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 430 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 431 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 432 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 433 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 434 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 435 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 436 AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 437 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
  • TABLE 438 AFRICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 439 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023-2030 (USD MILLION)
  • TABLE 440 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 441 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 442 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2022-2024
  • TABLE 443 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
  • TABLE 444 CELL THERAPY TECHNOLOGIES MARKET: REGION FOOTPRINT
  • TABLE 445 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT
  • TABLE 446 CELL THERAPY TECHNOLOGIES MARKET: CELL TYPE FOOTPRINT
  • TABLE 447 CELL THERAPY TECHNOLOGIES MARKET: APPLICATION FOOTPRINT
  • TABLE 448 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 449 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY PRODUCT AND REGION
  • TABLE 450 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
  • TABLE 451 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 452 CELL THERAPY TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 453 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 454 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 455 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
  • TABLE 456 DANAHER CORPORATION: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 457 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 458 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 459 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 460 MERCK KGAA: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 461 MERCK KGAA: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 462 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 463 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 464 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
  • TABLE 465 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 466 THERMO FISHER SCIENTIFIC INC: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 467 LONZA: COMPANY OVERVIEW
  • TABLE 468 LONZA: PRODUCTS OFFERED
  • TABLE 469 LONZA: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
  • TABLE 470 LONZA: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 471 LONZA: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 472 SARTORIUS AG: COMPANY OVERVIEW
  • TABLE 473 SARTORIUS AG: PRODUCTS OFFERED
  • TABLE 474 SARTORIUS AG: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 475 SARTORIUS AG: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 476 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 477 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 478 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
  • TABLE 479 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022- DECEMBER 2025
  • TABLE 480 AVANTOR, INC.: COMPANY OVERVIEW
  • TABLE 481 AVANTOR, INC.: PRODUCTS OFFERED
  • TABLE 482 AVANTOR, INC.: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
  • TABLE 483 AVANTOR, INC.: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 484 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW
  • TABLE 485 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED
  • TABLE 486 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 487 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
  • TABLE 488 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
  • TABLE 489 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
  • TABLE 490 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 491 CORNING INCORPORATED: COMPANY OVERVIEW
  • TABLE 492 CORNING INCORPORATED: PRODUCTS OFFERED
  • TABLE 493 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 494 TERUMO CORPORATION: PRODUCTS OFFERED
  • TABLE 495 TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
  • TABLE 496 TERUMO CORPORATION: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 497 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 498 BIO-TECHNE: COMPANY OVERVIEW
  • TABLE 499 BIO-TECHNE: PRODUCTS OFFERED
  • TABLE 500 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
  • TABLE 501 BIO-TECHNE: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 502 BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 503 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 504 GENSCRIPT: PRODUCTS OFFERED
  • TABLE 505 GENSCRIPT: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 506 GENSCRIPT: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 507 MAXCYTE: COMPANY OVERVIEW
  • TABLE 508 MAXCYTE: PRODUCTS OFFERED
  • TABLE 509 MAXCYTE: DEALS, JANUARY 2022-DECEMBER 2024
  • TABLE 510 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 511 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED
  • TABLE 512 STEMCELL TECHNOLOGIES: PRODUCT LAUNCHES, JANUARY 2022-DECEMBER 2025
  • TABLE 513 STEMCELL TECHNOLOGIES: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 514 ROOSTERBIO, INC.: COMPANY OVERVIEW
  • TABLE 515 MILTENYI BIOTEC: COMPANY OVERVIEW
  • TABLE 516 TRAKCEL: COMPANY OVERVIEW
  • TABLE 517 L7 INFORMATICS, INC.: COMPANY OVERVIEW
  • TABLE 518 REPLIGEN CORPORATION: COMPANY OVERVIEW
  • TABLE 519 MAK SYSTEM: COMPANY OVERVIEW
  • TABLE 520 ORIGEN BIOMEDICAL, INC.: COMPANY OVERVIEW
  • TABLE 521 IXCELLS BIOTECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 522 KORBER AG: COMPANY OVERVIEW
  • TABLE 523 KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW
  • TABLE 524 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
  • TABLE 525 CELL THERAPY TECHNOLOGIES MARKET: RISK ANALYSIS

List of Figures

  • FIGURE 1 CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: YEARS CONSIDERED
  • FIGURE 3 MARKET SCENARIO OF CELL THERAPY TECHNOLOGIES MARKET
  • FIGURE 4 GLOBAL CELL THERAPY TECHNOLOGIES MARKET, 2023-2030 (USD MILLION)
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2020-2025
  • FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF CELL THERAPY TECHNOLOGIES MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS IN CELL THERAPY TECHNOLOGIES MARKET, 2025-2030
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CELL THERAPY TECHNOLOGIES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 9 INCREASED FUNDING & INVESTMENT IN CELL THERAPY AND GROWING PRODUCT PIPELINE TO DRIVE MARKET
  • FIGURE 10 US AND T-CELLS DOMINATED LARGEST NORTH AMERCIAN MARKET SHARE IN 2024
  • FIGURE 11 MEDIA, SERA, AND REAGENTS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 15 GROWTH OF GLOBAL GDP FROM 2020 TO 2024, WITH FORECAST UNTIL 2030
  • FIGURE 16 CELL THERAPY TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 17 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2024 (USD)
  • FIGURE 18 VALUE CHAIN ANALYSIS IN CELL THERAPY TECHNOLOGIES MARKET
  • FIGURE 19 GOVERNMENT FUNDING FOR R&D, 2019-2024
  • FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS IN CELL THERAPY TECHNOLOGIES MARKET
  • FIGURE 21 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL THERAPY TECHNOLOGIES PATENTS, 2014-2024
  • FIGURE 22 IMPACT OF AI IN CELL THERAPY TECHNOLOGIES MARKET
  • FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 24 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 25 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 26 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2022-2024 (USD MILLION)
  • FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET (2024)
  • FIGURE 29 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 30 CELL THERAPY TECHNOLOGIES MARKET: COMPANY FOOTPRINT
  • FIGURE 31 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 32 EV/EBITDA OF KEY VENDORS
  • FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • FIGURE 38 LONZA: COMPANY SNAPSHOT
  • FIGURE 39 SARTORIUS AG: COMPANY SNAPSHOT
  • FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • FIGURE 41 AVANTOR, INC.: COMPANY SNAPSHOT
  • FIGURE 42 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT
  • FIGURE 43 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT
  • FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT
  • FIGURE 45 TERUMO CORPORATION: COMPANY SNAPSHOT
  • FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT
  • FIGURE 47 GENSCRIPT: COMPANY SNAPSHOT
  • FIGURE 48 MAXCYTE: COMPANY SNAPSHOT
  • FIGURE 49 CELL THERAPY TECHNOLOGIES MARKET: RESEARCH DESIGN
  • FIGURE 50 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 51 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 52 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024
  • FIGURE 53 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE SHARE ANALYSIS (2024)
  • FIGURE 54 CELL THERAPY TECHNOLOGIES MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 55 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 56 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS
  • FIGURE 57 CELL THERAPY TECHNOLOGIES MARKET: DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!